EyePoint Pharmaceuticals, Inc. (EYPT)
NASDAQ: EYPT · Real-Time Price · USD
9.56
-0.40 (-4.02%)
Oct 24, 2024, 4:00 PM EDT - Market closed
EyePoint Pharmaceuticals Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for EYPT stock have an average target of 27.71, with a low estimate of 15 and a high estimate of 44. The average target predicts an increase of 189.85% from the current stock price of 9.56.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for EYPT stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 3 | 3 | 4 | 4 | 4 |
| Buy | 3 | 3 | 3 | 3 | 3 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 6 | 6 | 7 | 7 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Scotiabank | Scotiabank | Buy Initiates $18 | Buy | Initiates | $18 | +88.28% | Oct 16, 2024 |
| Jefferies | Jefferies | Strong Buy Initiates $15 | Strong Buy | Initiates | $15 | +56.90% | Aug 28, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $32 → $29 | Buy | Maintains | $32 → $29 | +203.35% | Aug 13, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $28 | Strong Buy | Maintains | $28 | +192.89% | Jun 28, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +213.81% | Jun 27, 2024 |
Financial Forecast
Revenue This Year
41.48M
from 46.02M
Decreased by -9.86%
Revenue Next Year
14.19M
from 41.48M
Decreased by -65.79%
EPS This Year
-2.41
from -1.82
EPS Next Year
-3.23
from -2.41
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 59.9M | 25.0M | 10.5M | ||
| Avg | 41.5M | 14.2M | 3.8M | ||
| Low | 20.8M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 30.1% | -39.6% | -26.0% | ||
| Avg | -9.9% | -65.8% | -73.2% | ||
| Low | -54.9% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.19 | -2.54 | -2.37 | ||
| Avg | -2.41 | -3.23 | -3.53 | ||
| Low | -2.53 | -4.03 | -4.71 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.